Troglitazone Improves Defects in Insulin Action, Insulin Secretion, Ovarian Steroidogenesis, and Fibrinolysis in Women with Polycystic Ovary Syndrome1
The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Abstract
Women with polycystic ovary syndrome (PCOS) are characterized by defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis. We administered the insulin-sensitizing agent troglitazone to 13 obese women with PCOS and impaired glucose tolerance to determine whether attenuation of hyperinsulinemia ameliorates these defects. All subjects had oligomenorrhea, hirsutism, polycystic ovaries, and hyperandrogenemia. Before and after treatment with troglitazone (400 mg daily for 12 weeks), all had 1) a GnRH agonist (leuprolide) test, 2) a 75-g oral glucose tolerance test, 3) a frequently sampled iv glucose tolerance test to determine the insulin sensitivity index and the acute insulin response to glucose, 4) an oscillatory glucose infusion to assess the ability of the beta-cell to entrain to glucose as quantitated by the normalized spectral power for the insulin secretion rate, and 5) measures of fibrinolytic capacity [plasminogen activator inhibitor type 1 (PAI-1) and tissue plasminogen activator]. There was no change in body mass index (39.9 +/- 1.4 vs. 40.2 +/- 1.4 kg/m2) or body fat distribution after treatment. Both the fasting (91 +/- 3 vs. 103 +/- 3 mg/dL; P < 0.001) and 2 h (146 +/- 8 vs. 171 +/- 6 mg/dL; P < 0.02) plasma glucose concentrations during the oral glucose tolerance test declined significantly. There was a concordant reduction in glycosylated hemoglobin to 5.7 +/- 0.1 from a pretreatment level of 6.1 +/- 0.1% (P < 0.03). Insulin sensitivity increased from 0.58 +/- 0.14 to 0.95 +/- 0.26 10(-5) min-1/pmol.L (P < 0.01) after treatment as did the disposition index (745 +/- 135 vs. 381 +/- 96; P < 0.05). The ability of the beta-cell to appropriately detect and respond to an oscillatory glucose infusion improved significantly after troglitazone treatment; the normalized spectral power for the insulin secretion rate increased to 5.9 +/- 1.1 from 4.3 +/- 0.8 (P < 0.05). Basal levels of total testosterone (109.3 +/- 15.2 vs. 79.4 +/- 9.8 ng/dL; P < 0.05) and free testosterone (33.3 +/- 4.0 vs. 21.2 +/- 2.6 pg/mL; P < 0.01) declined significantly after troglitazone treatment. Leuprolide-stimulated levels of 17-hydroxyprogesterone, androstenedione, and total testosterone were significantly lower posttreatment compared to pretreatment. The reduction in androgen levels occurred independently of any changes in gonadotropin levels. A decreased functional activity of PAI-1 in blood (from 12.7 +/- 2.8 to 6.3 +/- 1.4 AU/mL P < 0.05) was associated with a decreased concentration of PAI-1 protein (from 64.9 +/- 9.1 to 44.8 +/- 6.1 ng/mL; P < 0.05). No change in the functional activity of tissue plasminogen activator (from 5.3 +/- 0.4 to 5.1 +/- 0.5 IU/mL) was observed despite a decrease in its concentration (from 9.6 +/- 0.9 to 8.2 +/- 0.7 ng/mL; P < 0.05). The marked reduction in PAI-1 could be expected to improve the fibrinolytic response to thrombosis in these subjects. We conclude that administration of troglitazone to women with PCOS and impaired glucose tolerance ameliorates the metabolic and hormonal derangements characteristic of the syndrome. Troglitazone holds potential as a useful primary or adjunctive treatment for women with PCOS.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Low SHBG levels are also increased by insulin-sensitising medication (Ehrmann et al., 1997;Moghetti et al., 2000;Moran et al., 2013);”
From Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic–hyperinsulinaemic clamp studies (2016) · cites this paper as Ehrmann et al., 1997
Citations
Cites
Spectral Analysis and its Applications.
Freiberger, W. F., Jenkins, G. M., & Watts, D. G. (1969) · Journal of the American Statistical Association · doi:10.2307/2286100 · Cited by 4,981
Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,625
Morgan, C. R., & Lazarow, A. (1963) · Diabetes · doi:10.2337/diab.12.2.115 · Cited by 2,199
Kliewer, S. A., Lenhard, J. M., Willson, T. M., Patel, I., Morris, D. C., & Lehmann, J. M. (1995) · Cell · doi:10.1016/0092-8674(95)90194-9 · Cited by 2,028
Profound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome
Dunaif, A., Segal, K. R., Futterweit, W., & Dobrjansky, A. (1989) · Diabetes · doi:10.2337/diab.38.9.1165 · Cited by 1,967 · cited 2×
“It is important to note, however, that although insulin sensitivity improved in response to treatment, it remained profoundly depressed in these subjects and was disproportionate to the degree of obesity, as described previously ( 2 ).”
BackgroundBergman, R. N., Phillips, L. S., & Cobelli, C. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110398 · Cited by 1,640 · cited 3×
“Because the product of these measures is presumed to be constant ( 33 , 42, 43), a compensatory decrease in AIRg would be expected to accompany the increase in Si observed after troglitazone treatment.”
BackgroundMethodInfluentialMazess, R., Barden, H., Bisek, J., & Hanson, J. (1990) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/51.6.1106 · Cited by 1,476
Kahn, S. E., Prigeon, R. L., McCulloch, D. K., Boyko, E. J., Bergman, R. N., Schwartz, M. W., Neifing, J. L., Ward, W. K., Beard, J. C., & Palmer, J. P. (1993) · Diabetes · doi:10.2337/diab.42.11.1663 · Cited by 1,405 · cited 4×
“The product of Si and AIRg (disposition index) was also derived and provides a measure of b-cell secretory function adjusted for insulin sensitivity, previously described as a constant in any individual ( 43 ).”
BackgroundMethodInfluentialThiazolidinediones in the Treatment of Insulin Resistance and Type II Diabetes
Saltiel, A. R., & Olefsky, J. M. (1996) · Diabetes · doi:10.2337/diab.45.12.1661 · Cited by 1,053 · cited 1×
“Although the precise mechanism of action of troglitazone remains incompletely defined, it appears to enhance insulin action without directly stimulating insulin secretion ( 50 ) and acts as a selective ligand for the peroxisome proliferator-activated receptor-g (51).”
BackgroundToward Physiological Understanding of Glucose Tolerance: Minimal-Model Approach
Bergman, R. N. (1989) · Diabetes · doi:10.2337/diab.38.12.1512 · Cited by 1,001
Cited by
Items 301–400 of 485
Troglitazone Induces CYP3A4 Activity Leading to Falsely Abnormal Dexamethasone Suppression Test
Dimaraki, E. V., & Jaffe, C. A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021778 · Cited by 24
The polycystic ovary syndrome: treatment with insulin sensitizing agents
Iuorno, M. J., & Nestler, J. E. (1999) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.1999.00026.x · Cited by 23
7 Relation of functional ovarian hyperandrogenism to non-insulin dependent diabetes mellitus
Ehrmann, D. A. (1997) · Baillière s Clinical Obstetrics and Gynaecology · doi:10.1016/s0950-3552(97)80040-5 · Cited by 23
Self-citationEffects of glycemic control and other determinants on vascular disease in type 2 diabetes
Sobel, B. E. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01277-9 · Cited by 23
Self-citationPeroxisome proliferator-activated receptor γ and atherosclerosis
Marx, N. (2002) · Current Hypertension Reports · doi:10.1007/s11906-002-0056-8 · Cited by 23
Connolly, A., Leblanc, S., & Baillargeon, J. (2018) · International Journal of Endocrinology · doi:10.1155/2018/4315413 · Cited by 23
Jellinger, P. S., Dickey, R. A., & Ganda, P. (2000) · Cited by 22
Physiology and Pathology of the Female Reproductive Axis
Bulun, S. E. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00017-4 · Cited by 34
Pershadsingh, H. A. (1999) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.8.11.1859 · Cited by 23
Sobel, B. E. (2003) · Frontiers in bioscience · doi:10.2741/1140 · Cited by 22
Self-citationCalcaterra, V., Magenes, V. C., Bianchi, A., Rossi, V., Gatti, A., Marin, L., Vandoni, M., & Zuccotti, G. (2024) · Life · doi:10.3390/life14091198 · Cited by 23
Christopoulos, P., Mastorakos, G. P., Gazouli, M., Deligeoroglou, E., Katsikis, I., Diamanti‐Kandarakis, E., Panidis, D., & Creatsas, G. C. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05647.x · Cited by 21
Mieszczanska, H. Z., Kaba, N. K., Francis, C. W., Gerich, J. E., Dodis, R., Schwarz, K. Q., Phipps, R. P., SMITH, B. H., Lee, M. M.-S., Messing, S. P., et al. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02442.x · Cited by 20
Forouhi, N. G., Rumley, A., Lowe, G. D. O., McKeigue, P., & Sattar, N. A. (2003) · Blood Coagulation & Fibrinolysis · doi:10.1097/00001721-200312000-00011 · Cited by 23
Kumbak, B., & Kahraman, S. (2009) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1080/00016340902835919 · Cited by 19
Pharmacogenetics of Thiazolidinedione Therapy
Aquilante, C. L. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.8.917 · Cited by 19
Ovulation induction for polycystic ovary syndrome
Balen, A. H. (2000) · Human Fertility · doi:10.1080/1464727002000198791 · Cited by 19
Insulin resistance and polycystic ovary syndrome
Ehrmann, D. A. (2002) · Current Diabetes Reports · doi:10.1007/s11892-002-0061-y · Cited by 24
Self-citationInsulin Sensitizers and Antiandrogens in the Treatment of Polycystic Ovary Syndrome
Diamanti‐Kandarakis, E., & Zapanti, E. D. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06231.x · Cited by 19
Arlt, W., Neogi, P., Gross, C., & Miller, W. L. (2004) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0320425 · Cited by 22
Use of insulin-sensitizing agents in the treatment of polycystic ovary syndrome
(2008) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.08.004 · Cited by 23
New developments in type 2 diabetes mellitus: Combination therapy with a thiazolidinedione
Braunstein, S. N. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80195-9 · Cited by 19
Elkind-Hirsch, K. E. (2006) · Treatments in Endocrinology · doi:10.2165/00024677-200605030-00005 · Cited by 20
Guido, M., Pavone, V., Ciampelli, M., Murgia, F., Fulghesu, A. M., Apa, R., Caruso, A., Mancuso, S., & Lanzone, A. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.5.4775 · Cited by 17
Schneider, D. J., & Sobel, B. E. (2005) · Humana Press eBooks · doi:10.1385/1-59259-908-7:107 · Cited by 17
Self-citationOhn, J., Son, H., Yu, D., Kim, M. S., Kwon, S., Park, W.-S., Kim, J., & Kwon, O. (2022) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2022.02.011 · Cited by 18
Recent advances in the treatment of polycystic ovary syndrome
Yıldız, B. O. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.10.1295 · Cited by 20
Chronic anovulation and the polycystic ovary syndrome
KASE, N. G. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139003254.012 · Cited by 16
Third Annual World Congress on the Insulin Resistance Syndrome
Bloomgarden, Z. T. (2006) · Diabetes Care · doi:10.2337/dc06-zb09 · Cited by 17
Thiazolidinediones: Potential Link Between Insulin Resistance and Cardiovascular Disease
Aroda, V. R., & Henry, R. R. (2003) · Diabetes Spectrum · doi:10.2337/diaspect.16.2.120 · Cited by 16
Kagan, J. (1998) · Disease Markers · doi:10.1155/1998/698239 · Cited by 22
Nezi, M., CHRISTOPOULOS, P. F., Paltoglou, G., Gryparis, A., Bakoulas, V., Deligeoroglou, E., Creatsas, G. C., & Mastorakos, G. P. (2016) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2015-0312 · Cited by 15
Long, M. J., Sairam, M. R., & Komar, C. M. (2009) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-7-145 · Cited by 15
Minireview: Up-date management of non responder to clomiphene citrate in polycystic ovary syndrome.
Amin, M., Abdel-Kareem, O., Takekida, S., Moriyama, T., el-Aal, G. A., & Maruo, T. (2003) · PubMed · doi:10.24546/00386993 · Cited by 17
Polycystic ovary syndrome and metabolic syndrome: the worrisome twosome?
Shah, D., & Rasool, S. (2015) · Climacteric · doi:10.3109/13697137.2015.1116505 · Cited by 16
Çetinkalp, Ş., Karadeniz, M., Erdoğan, M., Zengi, A., Çetintaş, V. B., Vardarli, A. T., Eroğlu, Z., Kosova, B., Özgen, G., Saygılı, F., et al. (2008) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-008-9280-8 · Cited by 14
Hashimoto, S., Yatabe, J., Midorikawa, S., Sanada, H., & Watanabe, T. (2003) · Hormone Research in Paediatrics · doi:10.1159/000069064 · Cited by 14
Polycystic Ovarian Syndrome: the Next Cardiovascular Dilemma in Women?
Srikanthan, P., Korenman, S. G., & Davis, S. S. (2006) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2006.05.001 · Cited by 17
Comparison of metformin and thiazolidinediones in the management of polycystic ovary syndrome
Baillargeon, J., Iuorno, M. J., & Nestler, J. E. (2002) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/00060793-200208000-00003 · Cited by 14
Potential Cardiovascular Benefits of Insulin Sensitizers
Kunhiraman, B., Jawa, A., & Fonseca, V. A. (2005) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2004.11.005 · Cited by 14
Jawa, A., & Fonseca, V. A. (2005) · Cardiology Clinics · doi:10.1016/j.ccl.2004.06.001 · Cited by 14
Focus on the intermediate state: immature mRNA of cytochromes P450—methods and insights
Köhler, C. U., & Roos, P. H. (2008) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-008-2352-x · Cited by 13
The Fate of Beta-Cells in Type 2 Diabetes and the Possible Role of Pharmacological Interventions
Gallwitz, B. (2006) · The Review of Diabetic Studies · doi:10.1900/rds.2006.3.208 · Cited by 14
Insulin Resistance in Polycystic Ovarian Disease
Bhatia, V. (2005) · Southern Medical Journal · doi:10.1097/01.smj.0000177251.15366.85 · Cited by 15
Goacutemez-Peacuterez, F. J., Aguilar-Salinas, C. A., V[aacute]zquez-Ch[aacute]vez, C., nel-Salmoacuten, G. F., Gallegos-Mart[iacute]nez, J., Goacutemez-Diaz, R. A., Orozco, S. S., Chavira-Loacutepez, I. J., Saacutenchez-Reyes, L., Torres-Acosta, E. M., et al. (2002) · Metabolism · doi:10.1053/meta.2002.29024 · Cited by 13
A New Era for PPARγ: Covalent Ligands and Therapeutic Applications
King, J. L., Smithers, L., Vrielink, A., Lesterhuis, W. J., & Piggott, M. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02192 · Cited by 12
Matsushita, M., Tamura, K., Osada, S., & Kogo, H. (2005) · Endocrine · doi:10.1385/endo:27:3:301 · Cited by 12
Hara, S., Takahashi, T., Amita, M., Igarashi, H., Tsutsumi, S., & Kurachi, H. (2011) · Biology of Reproduction · doi:10.1095/biolreprod.111.090738 · Cited by 12
Role of GnRH drive in the pathophysiology of polycystic ovary syndrome
Leondires, M. P., & Berga, S. L. (1998) · Journal of Endocrinological Investigation · doi:10.1007/bf03347331 · Cited by 12
Çetinkalp, Ş., Karadeniz, M., Erdoğan, M., Özgen, G., Saygl, F., & Ylmaz, C. (2009) · The Endocrinologist · doi:10.1097/ten.0b013e3181a58772 · Cited by 15
New approaches to insulin resistance in polycystic ovarian syndrome
Davison, R. M. (1998) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/00001703-199806000-00003 · Cited by 13
The Pathogenesis of the Polycystic Ovary Syndrome: A Hypothesis
Gabrilove, J. L. (2002) · Endocrine Practice · doi:10.4158/ep.8.2.127 · Cited by 12
Anovulatory infertility and ovulation induction
Balen, A. H. (2007) · Cambridge University Press eBooks · doi:10.1017/cbo9781139696920.012 · Cited by 12
Le syndrome des ovaires polykystiques (SOPK)
Torre, A., & Fernandez, H. (2007) · Journal de gynécologie, obstétrique et biologie de la reproduction. Supplément/Journal de gynécologie obstétrique et biologie de la reproduction · doi:10.1016/j.jgyn.2007.04.002 · Cited by 22
Insulinoma, type 2 diabetes and plasminogen activator inhibitor type-I
Levine, R. A., & Sobel, B. E. (2001) · Coronary Artery Disease · doi:10.1097/00019501-200106000-00010 · Cited by 11
Self-citationThe 6th Annual World Congress on the Insulin Resistance Syndrome
Bloomgarden, Z. T. (2009) · Diabetes Care · doi:10.2337/dc09-zb09 · Cited by 13
Horikoshi, H., Hashimoto, T., & Fujiwara, T. (2000) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8391-7_6 · Cited by 12
Use of insulin sensitizing agents in the treatment of polycystic ovary syndrome
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.05.041 · Cited by 11
Insulin Resistance Effects on Sex Hormones and Ovulation in the Polycystic Ovary Syndrome
Nestler, J. E. (1999) · Humana Press eBooks · doi:10.1007/978-1-59259-716-1_19 · Cited by 11
Pathophysiology of Polycystic Ovarian Syndrome
Manu, Soni, T., Victoria, V., & Prabhakar, P. K. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.101921 · Cited by 15
Investigational agents that protect pancreatic islet β-cells from failure
Aston‐Mourney, K., Proietto, J., & Andrikopoulos, S. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.10.1241 · Cited by 11
The obstetrician-gynecologist’s role in the practical management of polycystic ovary syndrome
Berga, S. L. (1998) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(98)70241-8 · Cited by 10
Hyperinsulinaemia and polycystic ovary syndrome
Conway, G. S. (2000) · Human Fertility · doi:10.1080/1464727002000198761 · Cited by 10
Ovulation induction — Optimizing results and minimizing risks
Balen, A. H. (2003) · Human Fertility · doi:10.1080/1464770312331369263 · Cited by 10
Morris, R. S., Karande, V. C., Dudkiewicz, A. B., Morris, J. L., & Gleicher, N. (1999) · Fertility and Sterility · doi:10.1016/s0015-0282(98)00475-0 · Cited by 10
Perry, C. G., & Petrie, J. R. (1998) · Emerging Drugs · doi:10.1517/14728214.3.1.247 · Cited by 10
NASS, C. M., & Blumenthal, R. S. (2000) · PubMed · Cited by 10
Insulin Resistance and Atherosclerosis in Branch Retinal Vein Occlusion
Ogawa, O. (2003) · Japanese Journal of Ophthalmology · doi:10.1016/s0021-5155(03)00059-5 · Cited by 9
Glucose tolerance, insulin secretion and insulin sensitivity in polycystic ovary syndrome.
Pasquali, R., Pelusi, C., Ragazzini, C., Hasanaj, R., & Gambineri, A. (2002) · PubMed · Cited by 9
Ahmad, J., Shukla, N., Khan, A. R., Ahmed, F., & Siddiqui, M. A. (2008) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2007.12.003 · Cited by 8
Kassi, E. N., & Diamanti‐Kandarakis, E. (2008) · Journal of Endocrinological Investigation · doi:10.1007/bf03345663 · Cited by 9
Treatment strategies in PCOS patients
Weiss, J., Tauchert, S., Ludwig, A. K., & Diedrich, K. (2005) · Reproductive BioMedicine Online · doi:10.1016/s1472-6483(11)60393-3 · Cited by 10
Rao, L. N., Jacob, J. J., Paul, T. V., Rajarathinam, S., Thomas, N., & Seshadri, M. S. (2009) · Journal of Pediatric and Adolescent Gynecology · doi:10.1016/j.jpag.2008.08.005 · Cited by 8
Polycystic ovary syndrome: Not ovarian, not simple, unkind
Fox, R., & Ryan, A. (2002) · Human Fertility · doi:10.1080/1464727022000199881 · Cited by 8
Schuster, D., Gaillard, T. R., Rhinesmith, S., Habash, D., & Osei, K. (2003) · Metabolism · doi:10.1016/s0026-0495(03)00160-4 · Cited by 8
Molavi, B., Rasouli, N., & Mehta, J. L. (2002) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/107424840200700i101 · Cited by 9
Murphy, E., & Nolan, J. J. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.6.1347 · Cited by 9
Copperman, A. B., Mukherjee, T., & KASE, N. G. (2003) · Elsevier eBooks · doi:10.1016/b978-012053642-9/50029-6 · Cited by 7
Insulin Receptor and its Relationship with Different Forms of Insulin Resistance
Rojek, A., & Niedziela, M. (2010) · Postepy Biologii Komorki · doi:10.2478/v10052-010-0004-8 · Cited by 7
Dolfing, J. G., Tucker, K. E., Lem, C. M., Uittenbogaart, J., Verzijl, J. C., & Schweitzer, D. H. (2003) · Human Reproduction · doi:10.1093/humrep/deg082 · Cited by 7
Genetic contributions to glucose intolerance in polycystic ovary syndrome
Ehrmann, D. A. (2004) · Reproductive BioMedicine Online · doi:10.1016/s1472-6483(10)62106-2 · Cited by 7
Self-citation1 Endocrine methods of ovulation induction
Balen, A. H. (1998) · Baillière s Clinical Obstetrics and Gynaecology · doi:10.1016/s0950-3552(98)80049-7 · Cited by 8
New therapies in diabetes – thiazolidinediones
Smith, A. C., Fogelfeld, L. A., & Bakris, G. L. (2000) · Emerging Drugs · doi:10.1517/14728214.5.4.441 · Cited by 7
Die Insulinresistenz beim polyzystischen Ovar-Syndrom
Schröder, A. K., Tauchert, S., Ortmann, O., Diedrich, K., & Weiss, J. M. (2003) · Wiener klinische Wochenschrift · doi:10.1007/bf03041041 · Cited by 7
Cardiovascular Effects of Thiazolidinediones
Suwattee, P., Desouza, C. V., Asnani, S., Gilling, L., & Fonseca, V. A. (2002) · The Endocrinologist · doi:10.1097/00019616-200203000-00011 · Cited by 7
Effects of insulin-lowering drugs in PCOS: endocrine, metabolic and inflammatory aspects
Rautio, K. (2006) · Cited by 7
Interface between reproductive and metabolic dysfunction in polycystic ovary syndrome
Rasouli, M. A., Katz, J., & Dumesic, D. A. (2025) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000001037 · Cited by 6
López‐Bermejo, A., Casano, P., Petry, C. J., Jaramillo, A. M. A., Rodríguez‐González, F., Dunger, D. B., de Zegher, F., & Ibáñez, L. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.02914.x · Cited by 9
Wang, Y., Fedorcsák, P., Dale, P. O., Storeng, R., Åbyholm, T., & Tanbo, T. G. (2001) · Gynecological Endocrinology · doi:10.1080/gye.15.3.192.197 · Cited by 6
Plasminogen Activator Inhibitor-1 and Vascular Disease in Diabetes Mellitus
Vaughan, D. E. (2001) · Humana Press eBooks · doi:10.1007/978-1-59259-091-9_13 · Cited by 6
Use of insulin sensitizing agents in the treatment of polycystic ovary syndrome
(2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2006.08.043 · Cited by 6
Current procedures for managing polycystic ovary syndrome
Massicotte, M.-H., Langlois, F., & Baillargeon, J. (2009) · Expert Review of Obstetrics & Gynecology · doi:10.1586/eog.09.74 · Cited by 5
Endocrine and metabolic changes in women with polycystic ovaries and polycystic ovary syndrome
Koivunen, R. M. (2001) · Cited by 12
Stracquadanio, M. (2019) · Springer eBooks · doi:10.1007/978-3-030-29223-2_1 · Cited by 5
Diamanti‐Kandarakis, E., & KANDARAKIS, H. A. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1290.035 · Cited by 5
Cheang, K. I., Essah, P. A., & Nestler, J. E. (2004) · HORMONES · doi:10.14310/horm.2002.11133 · Cited by 5
Insulin Resistance and Lipotoxicity in PCOS: Causes and Consequences
Bellanger, S., Battista, M., & Baillargeon, J. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8394-6_7 · Cited by 9
Polycystic Ovary Syndrome and Hyperandrogenic States
Chang, R. J. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-4907-4.00020-6 · Cited by 6
Polycystic Ovary Syndrome and Hyperandrogenic States
Chang, R. J. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-2758-2.00022-6 · Cited by 4
AlRuthia, Y. S., Al-Mandeel, H. M., Alsanawi, H. A., Balkhi, B. S., Mansy, W., Algasem, R., & Almutairi, L. (2017) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2017.02.008 · Cited by 4
Metadata
- Authors
- Ehrmann, D. A., Schneider, D. J., Sobel, B. E., Cavaghan, M. K., Imperial, J., Rosenfield, R. L., & Polonsky, K. S.
- Affiliations
- University of Chicago (US)
- University of Vermont (US)
- Corresponding author
- Ehrmann, David A.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1997-07
- Volume
- 82
- Issue
- 7
- Pages
- 2108-2116
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2073637312
- Cited by
- 461
- References
- 67
- Citations by year
- 2025: 2 · 2024: 3 · 2022: 6 · 2021: 2 · 2019: 3 · 2018: 2 · 2017: 2 · 2016: 7 · 2015: 2 · 2014: 5 · 2013: 10 · 2012: 11
- FWCI
- 36.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5k08dk002315-02)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK-31842, DK 20595, DK-02315)
- NIH Clinical Center
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
- Keywords
- troglitazone, polycystic ovary syndrome, insulin resistance, insulin secretion, beta-cell function, ovarian steroidogenesis, fibrinolysis, plasminogen activator inhibitor-1, tissue plasminogen activator, hyperinsulinemia, impaired glucose tolerance, insulin sensitizers, hyperandrogenemia, obese women, leuprolide
- MeSH terms
- Troglitazone, Adult, Androgens, Chromans, Female, Fibrinolysis, Glucose, Glucose Tolerance Test, Gonadotropins, Humans, Insulin, Insulin Resistance, Polycystic Ovary Syndrome, Thiazoles, Leuprolide, Plasminogen Activator Inhibitor 1, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.